Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > June 22, 2020
Daily News
June 22, 2020
- Sakigake Status Awarded to GSK’s Next-Gen I/O Therapy, 2 More Drugs; System Possibly Subject to Review Next Time
June 22, 2020
- Lilly Japan Chief Sees Continued Diabetes Investment as Key to Remaining in Top 10
June 22, 2020
- MHLW Council Determines High Medical Needs for 2 Antiemetics
June 22, 2020
- Nobel Laureate Honjo Sues Ono over Opdivo Royalties, Demands 22.6 Billion Yen
June 22, 2020
- Shionogi Preparing Commercial Production of COVID-19 Vaccine Simultaneously with Development
June 22, 2020
- Sawai to Halt Erythromycin Shipment by July End due to Deviations from Specifications
June 22, 2020
- Oncolys Strikes Deal with Kagoshima Univ. to Develop COVID-19 Therapy
June 22, 2020
- MHLW Delays Chuikyo Discussion Timeline for Off-Year Price Survey, Drops June-End Goal
June 22, 2020
- Urovant, Sunovion Ink Distribution Pact for OAB Med Vibegron; Both Sumitomo Dainippon Units
June 22, 2020
- Pfizer Launches Celecox Authorized Generic, Its 1st AG
June 22, 2020
- Crysvita Approved for Tumor-Induced Osteomalacia in US: Kyowa Kirin/Ultragenyx
June 22, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…